lifespan.io – Join Us: Become a Lifespan Hero!
We are building public awareness and access to innovative treatments for controlling aging and age-related diseases!
- 57% Funded
- $2,896 per month
Related Organizations
Campaign List
Introducing the Public Longevity Group: Building the Future of Public Trust
Building the first public sentiment analysis engine to unlock public trust in longevity.
- 104% Funded
- $104,395 Funded
-
campaign
complete
Pearl: Participatory Evaluation of Aging with Rapamycin for Longevity
The first large-scale placebo-controlled clinical trial to determine the effects of Rapamycin on human longevity.
- 243% Funded
- $182,838 Funded
-
campaign
complete
MitoMouse: SENS Transgenic Mouse Project
Creating a transgenic mouse demonstrating the rescue of Mitochondrial DNA mutations in mammals. We will express the mitochondrial ATP8 gene from the nucleus as...
- 155% Funded
- $77,625 Funded
-
campaign
complete
Can NMN Increase Longevity?
The first long-term lifespan study in mice involving supplementation with NMN, a precursor of NAD+ metabolism, which has been shown to reduce aging markers and...
- 250% Funded
- $75,285 Funded
-
campaign
complete
MouseAge: Visual Biomarker for Mouse Aging
Using AI and Computer Vision Techniques to Determine Age and Assess the Effect of Therapies Against Aging in Mice, Increasing the Pace of Research.
- 130% Funded
- $19,508 Funded
-
campaign
complete
AgeMeter: Functional Age Biomarkers
Developing a diagnostic system to measure human functional age in comparison to chronological age, and assist in the assessment of anti-aging therapeutics.
- 100% Funded
- $30,061 Funded
-
campaign
complete
CellAge: Targeting Senescent Cells With Synthetic Biology
Designing better systems for detection and safe removal of dysfunctional “senescent” cells to improve health and treat age-related diseases.
- 171% Funded
- $34,215 Funded
-
campaign
complete
OncoSENS Control ALT Delete Cancer
High-throughput screening of a library of diverse drugs to find treatments for ‘ALT’ cancers, those which rely on Alternative Lengthening of Telomeres.
- 120% Funded
- $72,002 Funded
-
campaign
complete
The Major Mouse Testing Program
Testing a new class of compounds, Senolytics, on their ability to extend healthy lifespan by clearing out dysfunctional cells in the body.
- 115% Funded
- $52,075 Funded
-
campaign
complete
Articles from this author
May 15, 2026
Scientists have found a way to drastically ramp up mouse immune responses to cancer along with flu and COVID-19 [1]. How to wake up the immune system Modern cancer immunotherapies only work for a minority of patients. The reason, broadly, is that many tumors are immunologically “cold”: they do not trigger, and/or actively suppress, the...
May 14, 2026
Most cardiovascular trials focus on lowering LDL cholesterol or reducing inflammation to slow disease progression. UDP-003 targets the root cause: toxic 7-ketocholesterol (7KC) inside macrophages and soft plaques. It is designed to convert bloated foam cells back into healthy macrophages that can actively clear the hard plaque. This clinical trial took place at CMAX, a...
May 14, 2026
Cyclarity Therapeutics, Inc., a clinical stage biopharmaceutical company engineering cyclodextrin molecules into simple, scalable, and affordable therapies that bind and remove toxic targets to address root causes of age-related disease, has just unveiled data from a clinical trial of its lead candidate, UDP-003, at the American Heart Association Vascular Discovery Scientific Sessions. Data from a study...
May 13, 2026
This month, a group of researchers published an annual report on the clinical trials that are testing drugs for Alzheimer’s disease. Overall, they reported an increase in the number of trials, with 158 drugs investigated across 192 trials [1]. A growing problem The projections regarding the prevalence of Alzheimer’s disease are merciless. While in 2017,...
May 12, 2026
We are super excited to share with you that today we released AI4L - "AI for Practical Longevity", an open-source system that enables anyone to produce rigorous, evidence-based reviews of health and longevity interventions using frontier AI models. Our novel "Audit-Driven Prompting" method enables iterative self-auditing and eliminates hallucinations with live citation verification and zero-tolerance...
May 12, 2026
A new study suggests that GLP-1 receptor agonists do not affect muscle mass any more than weight loss caused by caloric restriction, and this appears to be true for strength as well [1]. What do we lose when we lose weight? GLP-1-based drugs, such as semaglutide and tirzepatide, have transformed obesity treatment. People on these...